Back to top

Image: Bigstock

Azul's August Traffic Improves From July, Load Factor Slips

Read MoreHide Full Article

With air-travel demand increasing gradually, Azul S.A. (AZUL - Free Report) reported impressive August traffic numbers on the back of month over month double-digit rise in domestic traffic. However, consolidated load factor (% of seats filled by passengers) dropped as consolidated traffic increase was less than the capacity expansion.

Consolidated load factor fell 4.1 percentage points month over month to 75.5%. In the international front, load factor declined 8.3 percentage point to 72.7% while in the domestic front the metric dropped 3.7 percentage points to 75.7%.

Consolidated traffic (measured in revenue passenger kilometers or RPKs) surged 26.4% on a month-over-month basis. While international traffic declined 4.3%, the metric soared 29.8% on the domestic front. Consolidated capacity (measured in available seat kilometers/ASKs) jumped 33.3% owing to 36.2% domestic expansion and 6.6% international expansion from the July reading.

In August, the carrier flew more than 40% of domestic capacity compared with the same period last year. During the month Azul noticed solid improvement in both booked average fares and revenue.

 Zacks Rank & Stocks to Consider

Azul currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the Zacks Transportation sector are Knight-Swift Transportation Holdings Inc. (KNX - Free Report) , Canadian Pacific Railway Limited (CP - Free Report) and Werner Enterprises, Inc. (WERN - Free Report) . Knight-Swift sports a Zacks Rank #1(Strong Buy), while Canadian Pacific and Werner carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Long-term expected earnings per share (three to five years) growth rate for Knight-Swift, Canadian Pacific and Werner is pegged at 15%, 8% and 8.5%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Published in